Nuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, China

2026-03-12 - 08:37

Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special Administrative Regions (SARs) in Greater China SHANGHAI, March 12, 2026 /PRNewswire/ — Today, Nuance Pharma (“Nuance”) announced that the Hong Kong Drug Office approved Ohtuvayre® (ensifentrine) for the maintenance treatment of chronic obstructive